28 results on '"Gensler, Lianne S."'
Search Results
2. Goodbye to the term ‘ankylosing spondylitis’, hello ‘axial spondyloarthritis’: time to embrace the ASAS-defined nomenclature
- Author
-
van der Heijde, Désirée, primary, Molto, Anna, additional, Ramiro, Sofia, additional, Braun, Jürgen, additional, Dougados, Maxime, additional, van Gaalen, Floris A, additional, Gensler, Lianne S, additional, Inman, Robert D, additional, Landewé, Robert B M, additional, Marzo-Ortega, Helena, additional, Navarro-Compán, Victoria, additional, Phoka, Andri, additional, Poddubnyy, Denis, additional, Protopopov, Mikhail, additional, Reveille, John, additional, Rudwaleit, Martin, additional, Sampaio-Barros, Percival, additional, Sepriano, Alexandre, additional, Sieper, Joachim, additional, Van den Bosch, Filip E, additional, van der Horst-Bruinsma, Irene, additional, Machado, Pedro M, additional, and Baraliakos, Xenofon, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies
- Author
-
Baraliakos, Xenofon, primary, Deodhar, Atul, additional, van der Heijde, Désirée, additional, Magrey, Marina, additional, Maksymowych, Walter P, additional, Tomita, Tetsuya, additional, Xu, Huji, additional, Massow, Ute, additional, Fleurinck, Carmen, additional, Ellis, Alicia M, additional, Vaux, Thomas, additional, Shepherd-Smith, Julie, additional, Marten, Alexander, additional, and Gensler, Lianne S, additional
- Published
- 2023
- Full Text
- View/download PDF
4. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
- Author
-
van der Heijde, Désirée, primary, Deodhar, Atul, additional, Baraliakos, Xenofon, additional, Brown, Matthew A, additional, Dobashi, Hiroaki, additional, Dougados, Maxime, additional, Elewaut, Dirk, additional, Ellis, Alicia M, additional, Fleurinck, Carmen, additional, Gaffney, Karl, additional, Gensler, Lianne S, additional, Haroon, Nigil, additional, Magrey, Marina, additional, Maksymowych, Walter P, additional, Marten, Alexander, additional, Massow, Ute, additional, Oortgiesen, Marga, additional, Poddubnyy, Denis, additional, Rudwaleit, Martin, additional, Shepherd-Smith, Julie, additional, Tomita, Tetsuya, additional, Van den Bosch, Filip, additional, Vaux, Thomas, additional, and Xu, Huji, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study
- Author
-
van der Heijde, Désirée, primary, Gensler, Lianne S, additional, Maksymowych, Walter P, additional, Landewé, Robert, additional, Rudwaleit, Martin, additional, Bauer, Lars, additional, Kumke, Thomas, additional, Kim, Mindy, additional, Auteri, Simone Emanuele, additional, Hoepken, Bengt, additional, and Deodhar, Atul, additional
- Published
- 2022
- Full Text
- View/download PDF
6. Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
- Author
-
Landewé, Robert BM, primary, Gensler, Lianne S, additional, Poddubnyy, Denis, additional, Rahman, Proton, additional, Hojnik, Maja, additional, Li, Xiaoqi, additional, Liu Leage, Soyi, additional, Adams, David, additional, Carlier, Hilde, additional, and Van den Bosch, Filip, additional
- Published
- 2021
- Full Text
- View/download PDF
7. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
- Author
-
Deodhar, Atul, primary, Sliwinska-Stanczyk, Paula, additional, Xu, Huji, additional, Baraliakos, Xenofon, additional, Gensler, Lianne S, additional, Fleishaker, Dona, additional, Wang, Lisy, additional, Wu, Joseph, additional, Menon, Sujatha, additional, Wang, Cunshan, additional, Dina, Oluwaseyi, additional, Fallon, Lara, additional, Kanik, Keith S, additional, and van der Heijde, Désirée, additional
- Published
- 2021
- Full Text
- View/download PDF
8. Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis
- Author
-
Li, Zhixiu, primary, Wu, Xin, additional, Leo, Paul J, additional, De Guzman, Erika, additional, Akkoc, Nurullah, additional, Breban, Maxime, additional, Macfarlane, Gary J, additional, Mahmoudi, Mahdi, additional, Marzo-Ortega, Helena, additional, Anderson, Lisa K, additional, Wheeler, Lawrie, additional, Chou, Chung-Tei, additional, Harrison, Andrew A, additional, Stebbings, Simon, additional, Jones, Gareth T, additional, Bang, So-Young, additional, Wang, Geng, additional, Jamshidi, Ahmadreza, additional, Farhadi, Elham, additional, Song, Jing, additional, Lin, Li, additional, Li, Mengmeng, additional, Wei, James Cheng-Chung, additional, Martin, Nicholas G, additional, Wright, Margaret J, additional, Lee, MinJae, additional, Wang, Yuqin, additional, Zhan, Jian, additional, Zhang, Jin-San, additional, Wang, Xiaobing, additional, Jin, Zi-Bing, additional, Weisman, Michael H, additional, Gensler, Lianne S, additional, Ward, Michael M, additional, Rahbar, Mohammad Hossein, additional, Diekman, Laura, additional, Kim, Tae-Hwan, additional, Reveille, John D, additional, Wordsworth, Bryan Paul, additional, Xu, Huji, additional, and Brown, Matthew A, additional
- Published
- 2021
- Full Text
- View/download PDF
9. Chronic back pain in first-degree relatives (FDRs) of patients with ankylosing spondylitis: predictive value of HLA-B27 and persistence of inflammatory back pain over time
- Author
-
Doughem, Karim, primary, Weisman, Michael H, additional, Ward, Michael M, additional, Gensler, Lianne S, additional, Ishimori, Mariko, additional, Tahanan, Amirali, additional, Kung, David C, additional, Diekman, Laura, additional, Lee, MinJae, additional, Rahbar, Mohammad Hossein, additional, and Reveille, John D, additional
- Published
- 2020
- Full Text
- View/download PDF
10. Association of body mass index on disease activity in axial spondyloarthritis: systematic review and meta-analysis
- Author
-
Liew, Jean W, primary, Huang, Irvin J, additional, Louden, Diana N, additional, Singh, Namrata, additional, and Gensler, Lianne S, additional
- Published
- 2020
- Full Text
- View/download PDF
11. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
- Author
-
van der Heijde, Désirée, primary, Gensler, Lianne S, additional, Deodhar, Atul, additional, Baraliakos, Xenofon, additional, Poddubnyy, Denis, additional, Kivitz, Alan, additional, Farmer, Mary Katherine, additional, Baeten, Dominique, additional, Goldammer, Nadine, additional, Coarse, Jason, additional, Oortgiesen, Marga, additional, and Dougados, Maxime, additional
- Published
- 2020
- Full Text
- View/download PDF
12. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials
- Author
-
Helliwell, Philip S, primary, Gladman, Dafna D, additional, Chakravarty, Soumya D, additional, Kafka, Shelly, additional, Karyekar, Chetan S, additional, You, Yin, additional, Campbell, Kim, additional, Sweet, Kristen, additional, Kavanaugh, Arthur, additional, and Gensler, Lianne S, additional
- Published
- 2020
- Full Text
- View/download PDF
13. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
- Author
-
Dougados, Maxime, primary, Wei, James Cheng-Chung, additional, Landewé, Robert, additional, Sieper, Joachim, additional, Baraliakos, Xenofon, additional, Van den Bosch, Filip, additional, Maksymowych, Walter P, additional, Ermann, Joerg, additional, Walsh, Jessica A, additional, Tomita, Tetsuya, additional, Deodhar, Atul, additional, van der Heijde, Désirée, additional, Li, Xiaoqi, additional, Zhao, Fangyi, additional, Bertram, Clinton C, additional, Gallo, Gaia, additional, Carlier, Hilde, additional, and Gensler, Lianne S, additional
- Published
- 2019
- Full Text
- View/download PDF
14. Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts
- Author
-
Boel, Anne, primary, Molto, Anna, additional, van der Heijde, Désirée, additional, Ciurea, Adrian, additional, Dougados, Maxime, additional, Gensler, Lianne S, additional, Santos, Maria-José, additional, De Miguel, Eugenio, additional, Poddubnyy, Denis, additional, Rudwaleit, Martin, additional, van Tubergen, Astrid, additional, van Gaalen, Floris A, additional, and Ramiro, Sofia, additional
- Published
- 2019
- Full Text
- View/download PDF
15. HLA class I and II alleles in susceptibility to ankylosing spondylitis
- Author
-
Reveille, John D, primary, Zhou, Xiaodong, additional, Lee, MinJae, additional, Weisman, Michael H, additional, Yi, Lin, additional, Gensler, Lianne S, additional, Zou, Hejian, additional, Ward, Michael M, additional, Ishimori, Mariko L, additional, Learch, Thomas J, additional, He, Dongyi, additional, Rahbar, Mohammad H, additional, Wang, Jiucun, additional, and Brown, Matthew A, additional
- Published
- 2018
- Full Text
- View/download PDF
16. Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis
- Author
-
Kiltz, Uta, primary, van der Heijde, Désirée, additional, Boonen, Annelies, additional, Akkoc, Nurullah, additional, Bautista-Molano, Wilson, additional, Burgos-Vargas, Ruben, additional, Wei, James Cheng-Chung, additional, Chiowchanwisawakit, Praveena, additional, Dougados, Maxime, additional, Duruoz, M Tuncay, additional, Elzorkany, Bassel Kamal, additional, Gaydukova, Inna, additional, Gensler, Lianne S, additional, Gilio, Michele, additional, Grazio, Simeon, additional, Gu, Jieruo, additional, Inman, Robert D, additional, Kim, Tae-Jong, additional, Navarro-Compan, Victoria, additional, Marzo-Ortega, Helena, additional, Ozgocmen, Salih, additional, Pimentel dos Santos, Fernando, additional, Schirmer, Michael, additional, Stebbings, Simon, additional, Van den Bosch, Filip E, additional, van Tubergen, Astrid, additional, and Braun, Juergen, additional
- Published
- 2018
- Full Text
- View/download PDF
17. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
- Author
-
Smolen, Josef S, primary, Schöls, Monika, additional, Braun, Jürgen, additional, Dougados, Maxime, additional, FitzGerald, Oliver, additional, Gladman, Dafna D, additional, Kavanaugh, Arthur, additional, Landewé, Robert, additional, Mease, Philip, additional, Sieper, Joachim, additional, Stamm, Tanja, additional, Wit, Maarten de, additional, Aletaha, Daniel, additional, Baraliakos, Xenofon, additional, Betteridge, Neil, additional, Bosch, Filip van den, additional, Coates, Laura C, additional, Emery, Paul, additional, Gensler, Lianne S, additional, Gossec, Laure, additional, Helliwell, Philip, additional, Jongkees, Merryn, additional, Kvien, Tore K, additional, Inman, Robert D, additional, McInnes, Iain B, additional, Maccarone, Mara, additional, Machado, Pedro M, additional, Molto, Anna, additional, Ogdie, Alexis, additional, Poddubnyy, Denis, additional, Ritchlin, Christopher, additional, Rudwaleit, Martin, additional, Tanew, Adrian, additional, Thio, Bing, additional, Veale, Douglas, additional, Vlam, Kurt de, additional, and Heijde, Désirée van der, additional
- Published
- 2017
- Full Text
- View/download PDF
18. ERAP2is associated with ankylosing spondylitis inHLA-B27-positive andHLA-B27-negative patients
- Author
-
Robinson, Philip C, primary, Costello, Mary-Ellen, additional, Leo, Paul, additional, Bradbury, Linda A, additional, Hollis, Kelly, additional, Cortes, Adrian, additional, Lee, Seunghun, additional, Joo, Kyung Bin, additional, Shim, Seung-Cheol, additional, Weisman, Michael, additional, Ward, Michael, additional, Zhou, Xiaodong, additional, Garchon, Henri-Jean, additional, Chiocchia, Gilles, additional, Nossent, Johannes, additional, Lie, Benedicte A, additional, Førre, Øystein, additional, Tuomilehto, Jaakko, additional, Laiho, Kari, additional, Jiang, Lei, additional, Liu, Yu, additional, Wu, Xin, additional, Elewaut, Dirk, additional, Burgos-Vargas, Ruben, additional, Gensler, Lianne S, additional, Stebbings, Simon, additional, Haroon, Nigil, additional, Mulero, Juan, additional, Fernandez-Sueiro, Jose Luis, additional, Gonzalez-Gay, Miguel A, additional, Lopez-Larrea, Carlos, additional, Bowness, Paul, additional, Gafney, Karl, additional, Gaston, John S Hill, additional, Gladman, Dafna D, additional, Rahman, Proton, additional, Maksymowych, Walter P, additional, Xu, Huji, additional, van der Horst-Bruinsma, Irene E, additional, Chou, Chung-Tei, additional, Valle-Oñate, Raphael, additional, Romero-Sánchez, María Consuelo, additional, Hansen, Inger Myrnes, additional, Pimentel-Santos, Fernando M, additional, Inman, Robert D, additional, Martin, Javier, additional, Breban, Maxime, additional, Evans, David, additional, Reveille, John D, additional, Kim, Tae-Hwan, additional, Wordsworth, B Paul, additional, and Brown, Matthew A, additional
- Published
- 2015
- Full Text
- View/download PDF
19. MICA, a gene contributing strong susceptibility to ankylosing spondylitis
- Author
-
Zhou, Xiaodong, primary, Wang, Jiucun, additional, Zou, Hejian, additional, Ward, Michael M, additional, Weisman, Michael H, additional, Espitia, Maribel G, additional, Xiao, Xiangjun, additional, Petersdorf, Effie, additional, Mignot, Emmanuel, additional, Martin, Javier, additional, Gensler, Lianne S, additional, Scheet, Paul, additional, and Reveille, John D, additional
- Published
- 2013
- Full Text
- View/download PDF
20. Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials.
- Author
-
Brown MA, Rudwaleit M, van Gaalen FA, Haroon N, Gensler LS, Fleurinck C, Marten A, Massow U, de Peyrecave N, Vaux T, White K, Deodhar A, and van der Horst-Bruinsma I
- Abstract
Objectives: Acute anterior uveitis ('uveitis') is a common axial spondyloarthritis (axSpA) extramusculoskeletal manifestation. Interleukin (IL)-17 is implicated in its pathogenesis, however, there is conflicting evidence for IL-17A inhibition in uveitis management. We report pooled analyses of uveitis incidence in patients receiving bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, from phase 2b/3 trials., Methods: Data were pooled for patients receiving BKZ 160 mg or placebo in the double-blind treatment period of the phase 3 BE MOBILE 1 (NCT03928704; non-radiographic axSpA) and BE MOBILE 2 (NCT03928743; radiographic axSpA) trials. Data were separately pooled for patients treated with at least one BKZ dose in the BE MOBILE trials and their ongoing open-label extension (OLE; NCT04436640), and the phase 2b BE AGILE trial (NCT02963506; radiographic axSpA) and its ongoing OLE (NCT03355573). Uveitis rates and exposure-adjusted incidence rates (EAIR)/100 patient-years (PYs) are reported., Results: In the BE MOBILE 1 and 2 double-blind treatment period, 0.6% (2/349) of patients receiving BKZ experienced uveitis vs 4.6% (11/237) receiving placebo (nominal p=0.001; EAIR (95% CI): 1.8/100 PYs (0.2 to 6.7) vs 15.4/100 PYs (95% CI 7.7 to 27.5)). In patients with history of uveitis, EAIR was lower in patients receiving BKZ (6.2/100 PYs (95% CI 0.2 to 34.8); 1.9%) vs placebo (70.4/100 PYs (95% CI 32.2 to 133.7); 20.0%; nominal p=0.004). In the phase 2b/3 pool (N=848; BKZ exposure: 2034.4 PYs), EAIR remained low (1.2/100 PYs (95% CI 0.8 to 1.8))., Conclusions: Bimekizumab, a dual-IL-17A/F inhibitor, may confer protective effects for uveitis in patients with axSpA., Competing Interests: Competing interests: MAB: Grant/research support from UCB Pharma; consultant for Clementia, Grey Wolf Therapeutics, Incyte, Ipsen, Pfizer, Regeneron and Xinthera; speaker for Novartis and Pfizer; payment for expert testimony from Ipsen; participation on a Data Safety Monitoring Board or Advisory Board for Incyte, Ipsen and Regeneron. MR: Speakers bureau from AbbVie, Boehringer Ingelheim, Chugai, Eli Lilly, Janssen, Novartis, Pfizer and UCB Pharma; consultant of AbbVie, Eli Lilly, Novartis and UCB Pharma. FAvG: Grants from Jacobus Stichting, Novartis, Stichting ASAS, Stichting Vrienden van Sole Mio and UCB Pharma; consultant for AbbVie, ASAS, BMS, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer and UCB Pharma. NH: Consultant for AbbVie, Eli Lilly, Janssen, Novartis and UCB Pharma. LSG: Consultant for Eli Lilly, Janssen, Novartis, Pfizer and UCB Pharma; grant/research support from Novartis and UCB Pharma paid to institution; participation on a Data Safety Monitoring Board or Advisory Board for Acelyrin; member of the Spondylitis Association of America Medical Scientific Advisory Board and ASAS Executive Committee. CF, KW: Employee and shareholder of UCB Pharma. AM, UM, TV, NdP: Employees of UCB Pharma. AD: Speaker for Eli Lilly, Janssen, Novartis, Pfizer and UCB Pharma; consultant for BMS, Eli Lilly, Janssen, MoonLake, Novartis, Pfizer and UCB Pharma; grant/research support from BMS, Celgene, Eli Lilly, Janssen, MoonLake, Novartis, Pfizer and UCB Pharma; support for attending meetings and/or travel from Eli Lilly; participation on a Data Safety Monitoring Board or Advisory Board for BMS, Eli Lilly, Janssen, MoonLake, Novartis, Pfizer and UCB Pharma; member of the steering committee of GRAPPA. IvdH-B: Consultant for AbbVie, Eli Lilly, MSD, Novartis and UCB Pharma; unrestricted grants received for investigator-initiated studies from AbbVie, MSD, Pfizer and UCB Pharma; fees received for Lectures from AbbVie, BMS, MSD and Pfizer., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ on behalf of EULAR.)
- Published
- 2024
- Full Text
- View/download PDF
21. Goodbye to the term 'ankylosing spondylitis', hello 'axial spondyloarthritis': time to embrace the ASAS-defined nomenclature.
- Author
-
van der Heijde D, Molto A, Ramiro S, Braun J, Dougados M, van Gaalen FA, Gensler LS, Inman RD, Landewé RBM, Marzo-Ortega H, Navarro-Compán V, Phoka A, Poddubnyy D, Protopopov M, Reveille J, Rudwaleit M, Sampaio-Barros P, Sepriano A, Sieper J, Van den Bosch FE, van der Horst-Bruinsma I, Machado PM, and Baraliakos X
- Subjects
- Humans, Severity of Illness Index, Sacroiliac Joint diagnostic imaging, C-Reactive Protein, Spondylitis, Ankylosing diagnosis, Spondylarthritis diagnosis, Sacroiliitis diagnostic imaging
- Abstract
Ankylosing spondylitis (AS) is the historic term used for decades for the HLA-B27-associated inflammatory disease affecting mainly the sacroiliac joints (SIJ) and spine. Classification criteria for AS have radiographic sacroiliitis as a dominant characteristic. However, with the availability of MRI of SIJ, it could be demonstrated that the disease starts long before definite SIJ changes become visible on radiographs. The Assessment of SpondyloArthritis international Society, representing a worldwide group of experts reached consensus on changes in the nomenclature pertaining to axial spondyloarthritis (axSpA), such as the terminology of diagnosis and of assessment of disease activity tools. These are important changes in the field, as experts in axSpA are now in agreement that the term axSpA is the overall term for the disease. A further differentiation, of which radiographic versus non-radiographic is only one aspect, may be relevant for research purposes. Another important decision was that the terms AS and radiographic axSpA (r-axSpA) can be used interchangeably, but that the preferred term is r-axSpA. Based on the decision that axSpA is the correct terminology, a proposal was made to officially change the meaning of the ASDAS acronym to 'Axial Spondyloarthritis Disease Activity Score'. In addition, for simplification it was proposed that the term ASDAS (instead of ASDAS-CRP) should be preferred and applied to the ASDAS calculated with C reactive protein (CRP). It is hoped that these changes will be used consequently for education, in textbooks, manuscripts and presentations., Competing Interests: Competing interests: DvdH has received consulting fees from AbbVie, Argenx, Bayer, BMS, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Takeda, UCB Pharma. She is Director of Imaging Rheumatology bv, associate editor of ARD, editorial board member of J Rheumatol and RMD Open, advisor of ASAS. AM has received consulting fees from AbbVie, Amgen, BMS, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, UCB Pharma and Viatris. SR has received research grants and/or consulting fees from AbbVie, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, UCB, Sanofi. MD has received consulting fees from Pfizer, AbbVie, UCB, Amgen, BMS, Galapagos, Lilly, Novartis, Merck. FAvG has received consultation fees from Novartis, BMS, AbbVie, MSD, Janssen, Lily, UCB. LG has received research grants and/or consulting fees from AbbVie, Acelyrin, Eli Lilly, Fresenius Kabi, Janssen, Novartis, Pfizer, UCB. RDI has received consulting fees from Abbvie, Janssen, Novartis, UCB. RBML has received consulting fees from AbbVie, BMS, Galapagos, Eli-Lilly, Novartis, Jansen, Pfizer and UCB, is director of Rheumatology Consultancy BV and past-president and executive member of ASAS. HM-O has received grant support from Janssen, Novartis and UCB. Honoraria and/or speaker fees from AbbVie, Biogen, Eli-Lilly, Janssen, Moonlake, Novartis, Pfizer, Takeda and UCB. VN-C has received consultancy/speaker/research grants from Abbvie, BMS, Fresenius Kabi, Galapagos, Janssen, Lilly, Moonlake, MSD, Novartis, Pfizer, Roche, UCB. AP, Patient with AxSpa, Eupati Fellow, Patient Expert, Advocator, President of Cyprus League of People with Rheumatism, President of AGORA Federation, Secretary of Axial Spondylarthritis International Federation (ASIF), EULAR-Advocacy Committee Member-Pare Committee Member. DP has received research support from AbbVie, Eli Lilly, MSD, Novartis, Pfizer, consulting fees from AbbVie, Biocad, Bristol-Myers Squibb, Eli Lilly, Janssen, Moonlake, Novartis, Pfizer and UCB, and speaker fees from AbbVie, Canon, DKSH, Eli Lilly, Janssen, MSD, Medscape, Novartis, Peervoice, Pfizer and UCB. MP has received consulting fees from Novartis as well as support for attending meetings and/or travel from Abbvie, Jannsen, Novartis and UCB. MR has receieved consulting/speaker fees from Abbvie, Chugai, Boehringer, Eli-Lilly, Janssen, Novartis, UCB. PDS-B has received consulting/ speaker's fees from AbbVie, Celltrion, Eli Lilly, GSK, Janssen, Novartis, Pfizer and UCB. AS has received speaking and/or consulting fees from Abbvie, Novartis, UCB and Lilly. JS has received gees for consultancies and for being a member of speakers’ bureau from Abbvie, Merck, Novartis and UCB. FEVdB has received consulting fees from Abbvie, Amgen, Eli Lilly, Galapagos, Janssen, Moonlake, Novartis and UCB. IvdH-B has received consulting/speaker’s fees from UCB, Lilly, AbbVie, MSD, BMS, Novartis. PMM has received consulting/speaker’s fees from Abbvie, BMS, Celgene, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB. XB has received consulting/speaker’s fees Abbvie, Amgen, BMS, Chugai, Galapagos, Gilead, Lilly, MSD, Novartis, Pfizer, Roche, Sandoz, UCB, Zuellig Pharma and is Member of the Editorial Board of ARD, ASAS President and EULAR President Elect., (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ on behalf of EULAR.)
- Published
- 2024
- Full Text
- View/download PDF
22. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies.
- Author
-
Baraliakos X, Deodhar A, van der Heijde D, Magrey M, Maksymowych WP, Tomita T, Xu H, Massow U, Fleurinck C, Ellis AM, Vaux T, Shepherd-Smith J, Marten A, and Gensler LS
- Subjects
- Humans, Interleukin-17, Treatment Outcome, Double-Blind Method, Non-Radiographic Axial Spondyloarthritis, Spondylitis, Ankylosing drug therapy, Spondylarthritis diagnostic imaging, Spondylarthritis drug therapy, Antibodies, Monoclonal, Humanized
- Abstract
Objectives: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated superior efficacy versus placebo in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA) at Week 16. Here, the objective is to report the efficacy and safety of BKZ at Week 52., Methods: BE MOBILE 1 (nr-axSpA; NCT03928704) and BE MOBILE 2 (r-axSpA; NCT03928743) comprised a 16-week, double-blind, placebo-controlled period, then a 36-week maintenance period. From Week 16, all patients received subcutaneous BKZ 160 mg every 4 weeks., Results: Improvements versus placebo in Assessment of SpondyloArthritis International Society ≥40% response (primary endpoint), Ankylosing Spondylitis Disease Activity Score, high-sensitivity C-reactive protein levels and MRI inflammation of the sacroiliac joints/spine at Week 16 were sustained to Week 52 in BKZ-randomised patients. At Week 52, responses of patients switching from placebo to BKZ at Week 16 were comparable to BKZ-randomised patients. At Week 52, ≥1 treatment-emergent adverse events (TEAEs) were reported in 183 (75.0%) and 249 (75.5%) patients with nr-axSpA and r-axSpA, respectively. Serious TEAEs occurred in 9 (3.7%) patients with nr-axSpA and 20 (6.1%) patients with r-axSpA. Oral candidiasis was the most frequent fungal infection (nr-axSpA: 18 (7.4%); r-axSpA: 20 (6.1%)). Uveitis occurred in three (1.2%) and seven (2.1%) patients with nr-axSpA and r-axSpA, and inflammatory bowel disease in two (0.8%) and three (0.9%)., Conclusions: At Week 52, dual inhibition of IL-17A and IL-17F with BKZ resulted in sustained efficacy across the axSpA spectrum; the safety profile was consistent with the known safety of BKZ., Trial Registration Number: NCT03928704; NCT03928743., Competing Interests: Competing interests: XB: Speakers bureau for AbbVie, BMS, Chugai, Eli Lilly, Galapagos, MSD, Novartis, Pfizer and UCB Pharma; paid instructor for AbbVie, BMS, Chugai, Eli Lilly, Galapagos, MSD, Novartis, Pfizer and UCB Pharma; consultant of AbbVie, BMS, Chugai, Eli Lilly, Galapagos, Gilead, MSD, Novartis, Pfizer and UCB Pharma; grant/research support from Novartis and UCB Pharma. AAD: Speakers bureau for Janssen, Novartis and Pfizer; consultant for AbbVie, Amgen, Aurinia, BMS, Eli Lilly, Janssen, MoonLake, Novartis, Pfizer and UCB Pharma; grant/research support from AbbVie, BMS, Celgene, Eli Lilly, MoonLake, Novartis, Pfizer and UCB Pharma. DvdH: Consulting fees from AbbVie, Bayer, BMS, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Lilly, Novartis, Pfizer, Takeda and UCB Pharma; director of Imaging Rheumatology BV. MM: Consultancy fees from AbbVie, BMS, Eli Lilly, Novartis, Pfizer and UCB Pharma; research grants from AbbVie, BMS and UCB Pharma. WPM: Honoraria/consulting fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer and UCB Pharma; research grants from AbbVie, Pfizer and UCB Pharma; educational grants from AbbVie, Janssen, Novartis, and Pfizer; Chief Medical Officer for CARE ARTHRITIS. TT: Consultancy fees from AbbVie, Eli Lilly, Gilead, Novartis and Pfizer; speaker fees from AbbVie, Astellas, Bristol-Myers Squibb, Eisai, Eli Lilly, Janssen, Kyowa Kirin, Mitsubishi-Tanabe, Novartis and Pfizer. HX: Speaker for AbbVie, Janssen, Novartis, Pfizer, and UCB Pharma; consultant for AbbVie, Beigene, BioMap, IASO, Pfizer and UCB Pharma; clinical investigator for Peking-Tsinghua Center for Life Sciences. UM, CF, AME, TV, JS-S, AM: Employees of UCB Pharma. LSG: Grants from Novartis and UCB Pharma paid to institution; consulting fees from AbbVie, Acelyrin, Eli Lilly, Fresenius Kabi, Janssen, Novartis, Pfizer and UCB Pharma., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
23. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
- Author
-
Dougados M, Wei JC, Landewé R, Sieper J, Baraliakos X, Van den Bosch F, Maksymowych WP, Ermann J, Walsh JA, Tomita T, Deodhar A, van der Heijde D, Li X, Zhao F, Bertram CC, Gallo G, Carlier H, and Gensler LS
- Subjects
- Adalimumab administration & dosage, Double-Blind Method, Drug Substitution, Female, Humans, Male, Radiography, Severity of Illness Index, Spondylarthritis diagnostic imaging, Time Factors, Treatment Outcome, Antibodies, Monoclonal, Humanized administration & dosage, Antirheumatic Agents administration & dosage, Spondylarthritis drug therapy, Tumor Necrosis Factor Inhibitors administration & dosage
- Abstract
Objectives: To investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive (COAST-V) or tumour necrosis factor inhibitor (TNFi)-experienced (COAST-W)., Methods: Adults with active r-axSpA were randomised 1:1:1:1 (n=341) to 80 mg ixekizumab every 2 (IXE Q2W) or 4 weeks (IXE Q4W), placebo (PBO) or 40 mg adalimumab Q2W (ADA) in COAST-V and 1:1:1 (n=316) to IXE Q2W, IXE Q4W or PBO in COAST-W. At week 16, patients receiving ixekizumab continued their assigned treatment; patients receiving PBO or ADA were rerandomised 1:1 to IXE Q2W or IXE Q4W (PBO/IXE, ADA/IXE) through week 52., Results: In COAST-V, Assessment of SpondyloArthritis international Society 40 (ASAS40) responses rates (intent-to-treat population, non-responder imputation) at weeks 16 and 52 were 48% and 53% (IXE Q4W); 52% and 51% (IXE Q2W); 36% and 51% (ADA/IXE); 19% and 47% (PBO/IXE). Corresponding ASAS40 response rates in COAST-W were 25% and 34% (IXE Q4W); 31% and 31% (IXE Q2W); 14% and 39% (PBO/IXE). Both ixekizumab regimens sustained improvements in disease activity, physical function, objective markers of inflammation, QoL, health status and overall function up to 52 weeks. Safety through 52 weeks of ixekizumab was consistent with safety through 16 weeks., Conclusion: The significant efficacy demonstrated with ixekizumab at week 16 was sustained for up to 52 weeks in bDMARD-naive and TNFi-experienced patients. bDMARD-naive patients initially treated with ADA demonstrated further numerical improvements after switching to ixekizumab. Safety findings were consistent with the known safety profile of ixekizumab., Trial Registration Number: NCT02696785/NCT02696798., Competing Interests: Competing interests: MD has served as a consultant and received research grants from AbbVie, Eli Lilly and Company, Pfizer and UCB Pharma. JC-CW has served as a consultant and/or speaker and/or has received research grants from Abbott, Bristol-Myers Squibb, Celgene, Chugai, Eisai, Eli Lilly and Company, Janssen, Novartis, Pfizer, Sanofi-Aventis, TSH Taiwan and UCB Pharma. RL has served as a consultant and/or advisor and/or has received research grants from AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Galapagos, Merck, Novartis, Pfizer and UCB Pharma. RL is the director of Rheumatology Consultancy BV, a company that was indirectly contracted by Eli Lilly and Company to perform read services for the COAST program. JS has served as a consultant and/or speaker for AbbVie, Boehringer Ingelheim, Eli Lilly and Company, Janssen, Merck, Novartis, Pfizer, Roche and UCB Pharma. XB has served as a consultant and/or has received research grants from AbbVie, Bristol-Myers Squibb, Celgene, Janssen, MSD, Novartis, Pfizer, Roche and UCB Pharma. FVdB has served as a consultant and/or speaker and/or has received research grants from AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Merck, Novartis, Pfizer, Sanofi and UCB Pharma. WPM has served as a consultant and/or received honoraria and/or research/educational grants from AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly and Company, Galapagos, Janssen, Novartis, Pfizer and UCB Pharma, and is Chief Medical Officer of CARE Arthritis Limited. JE has served as a consultant and/or received research grants from AbbVie, Boehringer Ingelheim, Eli Lilly and Company, Janssen, Novartis, Pfizer, Takeda and UCB Pharma. JAW has been a consultant and/or received research grants from AbbVie, Amgen, Celgene, Eli Lilly and Company, Novartis, Pfizer and UCB Pharma. AD has been a consultant and/or received research support from AbbVie, Bristol-Myers Squibb, Eli Lilly and Company, Glaxo Smith & Klein, Janssen, Novartis, Pfizer and UCB Pharma. DvdH has been a consultant for AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi, Eli Lilly and Company, Galapagos, Gilead, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda and UCB Pharma and is a Director of Imaging Rheumatology BV. TT has been a consultant and speaker for AbbVie, Astellas, Bristol-Myers Squibb, Eisai, Eli Lilly and Company, Janssen, Mitsubishi Tanabe, Novartis, Pfizer and Takeda. XL, FZ, CCB, GG and HC are current employees and shareholders of Eli Lilly and Company. LSG has been a consultant and/or received research grants/support from AbbVie, Amgen, Eli Lilly and Company, Galapagos, Janssen, Novartis, Pfizer and UCB Pharma., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2020
- Full Text
- View/download PDF
24. HLA class I and II alleles in susceptibility to ankylosing spondylitis.
- Author
-
Reveille JD, Zhou X, Lee M, Weisman MH, Yi L, Gensler LS, Zou H, Ward MM, Ishimori ML, Learch TJ, He D, Rahbar MH, Wang J, and Brown MA
- Subjects
- Adult, Alleles, Asian People genetics, Black People genetics, Female, Genetic Predisposition to Disease ethnology, Humans, Male, Spondylitis, Ankylosing ethnology, White People genetics, Black or African American, Genetic Predisposition to Disease genetics, Histocompatibility Antigens Class I analysis, Histocompatibility Antigens Class II analysis, Racial Groups genetics, Spondylitis, Ankylosing genetics
- Abstract
Objective: To examine associations of HLA class I and class II alleles with ankylosing spondylitis (AS) in three cohorts of patients of European, Asian and African ancestry., Methods: HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1 and HLA-DPB1 alleles were genotyped in 1948 unrelated white and 67 African-American patients with AS from the Prospective Study of Outcomes in Ankylosing Spondylitis cohort, the North American Spondylitis Consortium and Australo-Anglo-American Spondyloarthritis Consortium, 990 white and 245 African-American Controls and HLA-B alleles in 442 Han Chinese patients with AS and 346 controls from Shanghai and Gansu, China. In addition to the case:control analyses, HLA-B*27 -negative patients with AS were analysed separately, and logistic regression and 'relative predispositional effects' (RPE) analyses were carried out to control for the major effect of HLA-B*27 on disease susceptibility., Results: Although numerous associations were seen between HLA alleles and AS in whites, among HLA-B*27-negative patients with AS , positive associations were seen with HLA-A*29, B*38, B*49, B*52, DRB1*11 and DPB1*03:01 and negative associations with HLA-B*07, HLA-B*57, HLA-DRB1*15:01, HLA-DQB1*02:01 and HLA -DQB1*06:02 . Additional associations with HLA-B*14 and B*40 (B60) were observed via RPE analysis, which excludes the HLA-B*27 alleles. The increased frequency of HLA-B*40:01 and decreased frequency of HLA-B*07 was also seen in Han Chinese and African-Americans with AS. HLA-B*08 was decreased in whites with acute anterior uveitis., Conclusions: These data, analysing the largest number of patients with AS examined to date in three ethnic groups, confirm that other HLA class I and II alleles other than HLA-B*27 to be operative in AS predisposition., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2019
- Full Text
- View/download PDF
25. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.
- Author
-
Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, and van der Heijde D
- Subjects
- Advisory Committees, Axis, Cervical Vertebra, Consensus, Decision Making, Humans, Arthritis, Psoriatic therapy, Severity of Illness Index, Spondylitis, Ankylosing therapy
- Abstract
Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the results of a systematic literature review and expert opinion, a task force of rheumatologists, dermatologists, patients and a health professional developed an update of the 2012 recommendations. These underwent intensive discussions, on site voting and subsequent anonymous electronic voting on levels of agreement with each item. A set of 5 overarching principles and 11 recommendations were developed and voted on. Some items were present in the previous recommendations, while others were significantly changed or newly formulated. The 2017 task force arrived at a single set of recommendations for axial and peripheral SpA, including psoriatic arthritis (PsA). The most exhaustive discussions related to whether PsA should be assessed using unidimensional composite scores for its different domains or multidimensional scores that comprise multiple domains. This question was not resolved and constitutes an important research agenda. There was broad agreement, now better supported by data than in 2012, that remission/inactive disease and, alternatively, low/minimal disease activity are the principal targets for the treatment of PsA. As instruments to assess the patients on the path to the target, the Ankylosing Spondylitis Disease Activity Score (ASDAS) for axial SpA and the Disease Activity index for PSoriatic Arthritis (DAPSA) and Minimal Disease Activity (MDA) for PsA were recommended, although not supported by all. Shared decision-making between the clinician and the patient was seen as pivotal to the process. The task force defined the treatment target for SpA as remission or low disease activity and developed a large research agenda to further advance the field., Competing Interests: Competing interests: DA served as a consultant and/or speaker for Abbvie, Astra-Zeneca, BMS, Janssen, Medac, MSD, Pfizer, Roche, UCB and received grant support from BMS. XB has served as consultant and/or speaker for Abbvie, BMS, Celgene, Chugai, Janssen, Novartis, Pfizer, UCB. NB has received consultancy fees for work commissioned by Grünenthal, Lilly, Janssen, PfizerLaura Coates has received research funding from Abbvie and Janssen and honoraria from Abbvie, Amgen, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Pfizer, Sun Pharma, UCBMaxime Dougados has participated as a speaker in symposia or as an advisor in boards organized by Pfizer, Abbvie, Ucb, Merck, Amgen, Novartis, Lilly, Bms, Roche and his department has received research grants from Pfizer, Abbvie, Ucb, Merck, Amgen, Novartis, Lilly, Bms, Roche. Laure Gossec has received honoraria or research funding from Abbvie, BMS, Celgene, Janseen, MSD, Novartis, Pfizer, Roche and UCB. PE has undertaken clinical trials and provided expert advice to Pfizer, MSD, Abbvie, BMS, UCB, Roche, Novartis, Samsung, Sandoz and Lilly. OF reports grants and personal fees from Novartis, personal fees from Pfizer, personal fees from Lilly, personal fees from Cellgene, grants and personal fees from Abbvie, personal fees from Janssen, personal fees from UCB, outside the submitted work. AK has served as consultant and/or performed clinical research for Abbvie, Amgen, Celgene, Janssen, Novartis, UCB. PMM has received consultancy/speaker’s fees from AbbVie, Centocor, Janssen, Merck, Novartis, Pfizer and UCB. AM has received honoraria from Abbvie, MSD and UCBDP has received Grant/research support from: AbbVie, MSD, Novartis, Pfizer, has honoraria/speaker fees from AbbVie, BMS, Boehringer, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, and UCB. MR has received honoraria/ consultancies from Abbvie, BMS, Celgene, Chugai/Roche, Janssen, MSD, Novartis, Pfizer, UCB. JS has received grant support from and/or provided expert advice to Abbvie, Amgen, Astra-Zeneca, BMS, Boehringer-Ingelheim, Celgene, Celltrion, Gilead, Glaxo, Iltoo, Janssen, Lilly, Pfizer, MSD, Roche, Samsung, Novartis-Sandoz, UCB. TS has received honoraria from Abbvie, Janssen, MSD, Novartis and Roche and grant support from Abbvie. FVB has received speaker and/or consultancy fees from AbbVie, Celgene, Janssen,Lilly, MSD, Novartis, Pfizer and UCB. DH has received consulting fees Afrom bbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Daiichi, Eli-Lilly, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, UCB, and is Director of Imaging Rheumatology bv. MW has received consulting fees for lectures or advisory board meetings from Abbvie, BMS, Celgene, Eli Lilly, Novartis and Roche., (© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.)
- Published
- 2018
- Full Text
- View/download PDF
26. ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients.
- Author
-
Robinson PC, Costello ME, Leo P, Bradbury LA, Hollis K, Cortes A, Lee S, Joo KB, Shim SC, Weisman M, Ward M, Zhou X, Garchon HJ, Chiocchia G, Nossent J, Lie BA, Førre Ø, Tuomilehto J, Laiho K, Jiang L, Liu Y, Wu X, Elewaut D, Burgos-Vargas R, Gensler LS, Stebbings S, Haroon N, Mulero J, Fernandez-Sueiro JL, Gonzalez-Gay MA, Lopez-Larrea C, Bowness P, Gafney K, Gaston JS, Gladman DD, Rahman P, Maksymowych WP, Xu H, van der Horst-Bruinsma IE, Chou CT, Valle-Oñate R, Romero-Sánchez MC, Hansen IM, Pimentel-Santos FM, Inman RD, Martin J, Breban M, Evans D, Reveille JD, Kim TH, Wordsworth BP, and Brown MA
- Subjects
- Aminopeptidases immunology, Genetic Loci, Haplotypes, Humans, Logistic Models, Spondylitis, Ankylosing immunology, Aminopeptidases genetics, HLA-B27 Antigen analysis, Spondylitis, Ankylosing genetics
- Published
- 2015
- Full Text
- View/download PDF
27. Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis.
- Author
-
Cortes A, Maksymowych WP, Wordsworth BP, Inman RD, Danoy P, Rahman P, Stone MA, Corr M, Gensler LS, Gladman D, Morgan A, Marzo-Ortega H, Ward MM, Learch TJ, Reveille JD, Brown MA, and Weisman MH
- Subjects
- Adult, Cyclooxygenase 1 genetics, Exons genetics, Female, Genotype, Haplotypes genetics, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide genetics, Radiography, Receptor Activator of Nuclear Factor-kappa B genetics, Severity of Illness Index, Bone Resorption genetics, Cervical Vertebrae diagnostic imaging, Genetic Association Studies, Lumbar Vertebrae diagnostic imaging, Osteogenesis genetics, Spondylitis, Ankylosing diagnostic imaging, Spondylitis, Ankylosing genetics
- Abstract
Objective: To identify genetic associations with severity of radiographic damage in ankylosing spondylitis (AS)., Method: We studied 1537 AS cases of European descent; all fulfilled the modified New York Criteria. Radiographic severity was assessed from digitised lateral radiographs of the cervical and lumbar spine using the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS). A two-phase genotyping design was used. In phase 1, 498 single nucleotide polymorphisms (SNPs) were genotyped in 688 cases; these were selected to capture >90% of the common haplotypic variation in the exons, exon-intron boundaries, and 5 kb flanking DNA in the 5' and 3' UTR of 74 genes involved in anabolic or catabolic bone pathways. In phase 2, 15 SNPs exhibiting p<0.05 were genotyped in a further cohort of 830 AS cases; results were analysed both separately and in combination with the discovery phase data. Association was tested by contingency tables after separating the samples into 'mild' and 'severe' groups, defined as the bottom and top 40% by mSASSS, adjusted for gender and disease duration., Results: Experiment-wise association was observed with the SNP rs8092336 (combined OR 0.32, p=1.2×10(-5)), which lies within RANK (receptor activator of NFκB), a gene involved in osteoclastogenesis, and in the interaction between T cells and dendritic cells. Association was also found with the SNP rs1236913 in PTGS1 (prostaglandin-endoperoxide synthase 1, cyclooxygenase 1), giving an OR of 0.53 (p=2.6×10(-3)). There was no observed association between radiographic severity and HLA-B*27., Conclusions: These findings support roles for bone resorption and prostaglandins pathways in the osteoproliferative changes in AS., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.)
- Published
- 2015
- Full Text
- View/download PDF
28. MICA, a gene contributing strong susceptibility to ankylosing spondylitis.
- Author
-
Zhou X, Wang J, Zou H, Ward MM, Weisman MH, Espitia MG, Xiao X, Petersdorf E, Mignot E, Martin J, Gensler LS, Scheet P, and Reveille JD
- Subjects
- Adult, Asian statistics & numerical data, Cohort Studies, Female, Genetic Markers, Genetic Predisposition to Disease ethnology, Genetic Predisposition to Disease genetics, HLA-B Antigens genetics, Humans, Linkage Disequilibrium, Male, Middle Aged, Risk Factors, Spondylitis, Ankylosing ethnology, United States epidemiology, White People statistics & numerical data, Asian genetics, Histocompatibility Antigens Class I genetics, Spondylitis, Ankylosing genetics, White People genetics
- Abstract
Objective: The human major histocompatibility complex class I chain-related gene A (MICA) controls the immune process by balancing activities of natural killer cells, γδ T cells and αβ CD8 T cells, and immunosuppressive CD4 T cells. MICA is located near HLA-B on chromosome 6. Recent genomewide association studies indicate that genes most strongly linked to ankylosing spondylitis (AS) susceptibility come from the region containing HLA-B and MICA. While HLA-B27 is a well-known risk genetic marker for AS, the potential effect of linkage disequilibrium (LD) shields any associations of genes around HLA-B with AS. The aim of this study was to investigate a novel independent genetic association of MICA to AS., Methods: We examined 1543 AS patients and 1539 controls from two ethnic populations by sequencing MICA and genotyping HLA-B alleles. Initially, 1070 AS patients and 1003 controls of European ancestry were used as a discovery cohort, followed by a confirmation cohort of 473 Han Chinese AS patients and 536 controls. We performed a stratified analysis based on HLA-B27 carrier status. We also conducted logistic regression with a formal interaction term., Results: Sequencing of MICA identified that MICA*007:01 is a significant risk allele for AS in both Caucasian and Han Chinese populations, and that MICA*019 is a major risk allele in Chinese AS patients. Conditional analysis of MICA alleles on HLA-B27 that unshielded LD effect confirmed associations of the MICA alleles with AS., Conclusions: Parallel with HLA-B27, MICA confers strong susceptibility to AS in US white and Han Chinese populations., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.)
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.